Unicycive Therapeutics Files Proxy Statement Supplement
Ticker: UNCY · Form: DEFA14A · Filed: May 7, 2025 · CIK: 1766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | DEFA14A |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, filing-update
Related Tickers: UNIQ
TL;DR
UNIQ filed proxy docs, shareholders vote soon.
AI Summary
Unicycive Therapeutics, Inc. filed an amendment and supplement to its proxy statement for the upcoming Annual Meeting. This filing, dated May 7, 2025, is a definitive additional material related to the proxy statement previously filed under Schedule 14A. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides additional information to shareholders regarding the upcoming Annual Meeting, which is crucial for them to make informed voting decisions on company matters.
Risk Assessment
Risk Level: low — This is a routine filing of additional proxy materials, not indicating any immediate financial or operational risks.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Registrant
- 0001213900-25-040661.txt (document) — Filing identifier
- 20250507 (date) — Filing date
FAQ
What type of filing is this?
This is a Definitive Additional Material filing, supplementing the proxy statement for the Annual Meeting.
Who is the filing company?
The filing company is Unicycive Therapeutics, Inc.
When was this document filed?
This document was filed on May 7, 2025.
What is the purpose of this filing?
This filing serves as an amendment and supplement to the proxy statement for the Annual Meeting of Shareholders.
What is the company's standard industrial classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 7, 2025 regarding Unicycive Therapeutics, Inc. (UNCY).